Search

everythinglearnresearchcommunity

for

Search:↓

Anageninc stopping the sale of Pyrilutamide due to a cease and desist order from Kintor, with some speculating that it was either a hoax or subpar product.

The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

The conversation discusses how different factors can stimulate type 1 and type 2 isoforms of 5-alpha reductase, which are enzymes linked to hair loss. Specific treatments mentioned include oral Dutasteride and topical Finasteride.

The user experienced side effects from RU58841, including dry eyes and potential eyesight issues, and decided to stop using it. They confirmed the product's legitimacy but advised caution due to its experimental status and lack of safety data.

Kintor Pharma finished enrolling and dosing participants in a Phase I trial for a hair loss treatment called AR-PROTAC (GT20029). The effectiveness of another drug, pyrilutamide (KX-826), for hair loss will be clearer after a Phase 2 trial expected to complete in January 2023.

Dr. Kang-Yell Choi's company, CK Regeon, is developing a drug called KY19382 for hair regeneration, which involves creating fine wounds to activate stem cells. The drug is in the formulation development stage, targeting markets like the US and Korea.

RU58841 from rudirect caused more hair shedding and itch, while anageninc's RU58841 improved the situation. Users are concerned about the quality and authenticity of RU58841 from different suppliers, including those from China.

User tried oral finasteride, topical finasteride, topical dutasteride, and RU58841 but experienced side effects. They discuss upcoming treatments like clascoterone, pyrilutamide, gt20029, and KY19382 as potential options.

RU58841 is discussed as an effective hair loss treatment, with some users experiencing regrowth and reduced shedding, but concerns about safety and sourcing are raised. Users advise against purchasing from Amazon, recommending reputable sources and cautioning about potential side effects like cardiovascular issues.

A 23-year-old male is experiencing diffuse hair loss and miniaturization, possibly due to high IGE levels after using tofacitinib. He seeks advice and has not yet consulted a dermatologist.

RU58841 is not recommended for use around children due to potential exposure risks. Alternatives like CB-03-01 might be considered, but further research is advised.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The user is experiencing irritation from using PG with RU58841 and is seeking alternative solutions like K&B in the UK. They report redness, itchiness, and flaky skin from the current treatment.

The conversation is about using Biolabshop's RU58841 product, which includes GHK-Cu and melatonin, to improve hair quality and combat hair loss. The user has previously used finasteride, minoxidil, and Anageninc’s RU58841 with success and seeks feedback on the new product, especially from those on anabolic steroids or hormone treatments.

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.

KX-826 hair loss treatment completed trials with mild side effects. GT20029 may be ultimate cure, destroying androgen receptors causing baldness.

Replicel's results were delayed, but Shiseido might share data at BioJapan on October 11. Users are hopeful for new treatments like RCH-01, potentially eliminating the need for finasteride or minoxidil.

An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

RU58841 and Pyrilutamide (Kx-826) are both topical anti-androgens, but neither is effective for hair regrowth. RU58841 has more anecdotal support, while Pyrilutamide has progressed further in trials, though both have limitations.

The conversation discusses positive initial trial results for GT20029, a topical compound for hair loss that degrades androgen receptors, potentially requiring only weekly application. Participants express hope for this treatment to be more effective and convenient than current options like Minoxidil, Finasteride, and RU58841.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.

RU58841 not working for hair loss after 10 months. Concerns about purity of experimental drugs.

Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.

PP405 is a safer alternative to JXL069 for hair loss treatment because it penetrates the skin effectively and degrades in the blood, avoiding systemic toxicity. JXL069, when forced into the body, can cause dangerous side effects like lactic acidosis due to its inability to degrade safely.

Exploring potential treatments for hair loss, with the focus being on comparing RU58841 and Pyrilutamide. Finasteride, Dutasteride, oral Minoxidil, microneedling, topical Minoxidil, Biotin, Zinc, Vitamin D and Nizoral are also discussed as part of a treatment stack.

The conversation discusses hair loss treatments, with the original poster considering joining a clinical trial for setipiprant after experiencing side effects from finasteride and disinterest in minoxidil. Some users express skepticism about setipiprant's effectiveness, while others encourage participation in the trial for potential benefits.